Specifically, MYCN amplification and ATRX-inactivating mutations are incompatible in all stages of NB, leading to synthetic genetic lethality due to the excessive DNA-replicative stress caused by these alterations [32]. The gene discussed is MYCN; the disease is neuroblastoma.